Ocuphire Pharma Investor Day Presentation Deck
Presbyopia Eye Drops Competitive Landscape
Validation of Pupil Modulating Drops Achieving Pin-Hole Effect & Efficacy, Many with Pilocarpine
Other Cholinergic Agonists*
99
Pupil modulation MOA
Soften lens MOA
Combination drugs
*act on sphincter and
ciliary muscles in dose-
dependent manner
Cholinergic
Agonist*
(pilocarpine)
Visus
Lenz
(PRX-100;
(BrimocholⓇ;
brimonidine + aceclidine)
carbachol)
Eyenovia
(MicroLine;
2% pilo)
Allergan
(VUITY™M;
1.25% pilo)
NDA
Orasis
(CSF-1;
Low dose pilo)
Phase 3
Phase 2
Phase 1
Novartis
(EV-06)
Ocuphire
(0.75% Nyxol)
Alpha-1
Antagonist
Nyxol is differentiated
as a new MOA class
using the iris dilator muscle
to reach an optimal pupil size
Ocuphire
(0.75% Nyxol
+0.4% pilo) Alpha Antagonist
& pilocarpine*
Corporate Websites, Grzybowski, A, Markeviciute A, Zemaitiene R. A Review of Pharmacological Presbyopia Treatment. 2020
Ocuphire
PHARMAView entire presentation